Company news
GeoVax Labs, Inc. news in 2024
GeoVax Labs, Inc.'s news releases, calls and decks from 2024, newest first.
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
December 9, 2024
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
November 18, 2024
GeoVax Labs Reports Third Quarter 2024 Financial Results and Provides Business Update Form 8 K
November 13, 2024
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
November 11, 2024
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
November 4, 2024
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
August 28, 2024
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market
August 20, 2024
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
August 7, 2024
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
August 5, 2024
GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review
July 30, 2024
GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024
July 29, 2024
GeoVax Labs to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At the Market Form 8 K
July 12, 2024
GeoVax Provides First Half 2024 Business Update
July 8, 2024
GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA
June 26, 2024
GeoVax Labs Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next Generation COVID 19 Vaccine Candidate, GEO CM04S1 Form 8 K
June 19, 2024
GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1
June 17, 2024
GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update
May 13, 2024
GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
May 6, 2024
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
March 5, 2024
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
February 28, 2024
GeoVax Announces Multiple Patent Issuances and Allowances
February 12, 2024
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
February 5, 2024
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
January 28, 2024
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
January 7, 2024
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
January 3, 2024
GeoVax Announces Gedeptin Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
January 3, 2024
GeoVax Announces Issuance of Malaria Vaccine Patent
January 2, 2024